VYNE Therapeutics
VYNE
35 hedge funds and large institutions have $23.4M invested in VYNE Therapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 6 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
64% more capital invested
Capital invested by funds: $14.3M → $23.4M (+$9.12M)
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
6% more funds holding
Funds holding: 33 → 35 (+2)
1.93% less ownership
Funds ownership: 49.82% → 47.9% (-1.9%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$643K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$403K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$113K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$96.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$82.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$505K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$287K |
| 3 |
Renaissance Technologies
New York
|
-$161K |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$144K |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$131K |
VYNE Hedge Fund Activity: Q4 2024 in Review
35 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2024, worth a combined $23.4M — up 64% from $14.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VYNE positions and 6 closed out — a net gain of 3 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was UBS O'Connor, opening a new position worth an estimated $643K. The largest seller was AlphaCentric Advisors, exiting entirely with an estimated $505K sold.
- 35 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2024, up from 33 in Q3 2024.
- Funds reported $23.4M of VYNE Therapeutics stock for Q4 2024, up 64% quarter-over-quarter.
- 9 funds opened new VYNE Therapeutics positions in Q4 2024 and 6 closed out, a net change of +3 holders.
- The largest VYNE Therapeutics buyer in Q4 2024 was UBS O'Connor, an estimated $643K added.
- The largest VYNE Therapeutics seller in Q4 2024 was AlphaCentric Advisors, an estimated $505K sold.
Based on aggregated 13F filings for Q4 2024.